<unk>  <unk>  is a rare<unk>  syndrome associated with lung, ovarian, breast, Hodgkin’s lymphoma, and other types of tumors.<unk>  occurs in less than 1 to 3% of cancer patients. The pathogenesis of<unk>  is due to an autoimmune reaction targeted against components of the central nervous system. The presence of anti-Purkinje cell is triggered by tumor cells, that normally express a Purkinje neuronal protein termed CDR2 antibodies. The antibodies that have been associated with the development of<unk>  include anti-P/Q type calcium channel antibodies, anti-Tr antibodies, anti-Ri (ANNA-2), anti-CV2, antibodies to Ma proteins, and antibodies to the Zic4.<unk>  is more commonly observed among patients between 40 to 60 years old.<unk>  affects females more commonly than males. The majority of patients with<unk>  are typically symptomatic. Early clinical features include dizziness, nausea, and vomiting. The diagnosis of<unk>  is made with the following criteria: positive antibody-mediated immune response, diffuse<unk>  atrophy on imaging, and positive medical history of cancer. Common medical therapies for<unk>  include intravenous immunoglobulins, cyclophosphamide, and methylprednisolone. There are no primary and secondary preventive measures available for<unk> .
Paraneoplastic cerebellar degeneration
Idiopathic inflammatory demyelinating diseases
Central pontine myelinolysis
Chronic inflammatory demyelinating polyneuropathy
Cerebellar stroke syndrome
Acute flaccid myelitis
Amyotrophic lateral sclerosis
Acute disseminated encephalomyelitis